Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
Sponsor: Takeda
Summary
The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the anaplastic lymphoma kinase (ALK) gene. Other study aims are to learn about the progression of NSCLC and participants' response to treatment with brigatinib.
Official title: A Real-World Study to Evaluate the Effectiveness and Safety of Brigatinib in First Line in Patients With ALK Positive Locally Advanced or Metastatic NSCLC in China: An Ambispective, Non-interventional, Observational, Multi-center Study.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
154
Start Date
2024-01-17
Completion Date
2028-12-30
Last Updated
2026-02-18
Healthy Volunteers
No
Conditions
Interventions
Brigatinib
Brigatinib Tablets
Locations (1)
Department of Oncology, Shanghai pulmonary hospital
Shanghai, Shanghai Municipality, China